Literature DB >> 20962092

Induction of type I interferon secretion through recombinant Newcastle disease virus expressing measles virus hemagglutinin stimulates antibody secretion in the presence of maternal antibodies.

Dhohyung Kim1, Luis Martinez-Sobrido, Changsun Choi, Natasha Petroff, Adolfo García-Sastre, Stefan Niewiesk, Thomas Carsillo.   

Abstract

Measles virus (MV) vaccine effectively protects seronegative individuals against infection. However, inhibition of vaccine-induced seroconversion by maternal antibodies after vaccination remains a problem, as it leaves infants susceptible to MV infection. In cotton rats, passive transfer of MV-specific IgG mimics maternal antibodies and inhibits vaccine-induced seroconversion. Here, we report that immunization in the presence of passively transferred IgG inhibits the secretion of neutralizing antibodies but not the generation of MV-specific B cells. This finding suggested that MV-specific B cells require an additional stimulus to mature into antibody-secreting plasma cells. In order to provide such a stimulus, we generated a recombinant Newcastle disease virus (NDV) expressing the MV hemagglutinin (NDV-H). In contrast to MV, NDV-H induced high levels of type I interferon in plasmacytoid dendritic cells and in lung tissue. In cotton rats immunized with NDV-H, neutralizing antibodies were also generated in the presence of passively transferred antibodies. In the latter case, however, the level and kinetics of antibody generation were reduced. In vitro, alpha interferon stimulated the activation of MV-specific B cells from MV-immune spleen cells. NDV infection (which induces alpha interferon) had the same effect, and stimulation could be abrogated by antibodies neutralizing alpha interferon, but not interleukin 6 (IL-6). In vivo, coapplication of UV-inactivated MV with NDV led to increased MV-specific antibody production in the presence and absence of passively transferred antibodies. These data indicate that MV-specific B cells are being generated after immunization in the presence of maternal antibodies and that the provision of alpha interferon as an additional signal leads to antibody secretion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20962092      PMCID: PMC3014200          DOI: 10.1128/JVI.01624-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6.

Authors:  Gaetan Jego; A Karolina Palucka; Jean-Philippe Blanck; Cecile Chalouni; Virginia Pascual; Jacques Banchereau
Journal:  Immunity       Date:  2003-08       Impact factor: 31.745

2.  Inhibition of major histocompatibility complex class II-dependent antigen presentation by neutralization of gamma interferon leads to breakdown of resistance against measles virus-induced encephalitis.

Authors:  G Weidinger; G Henning; V ter Meulen; S Niewiesk
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

3.  Extent of measles virus spread and immune suppression differentiates between wild-type and vaccine strains in the cotton rat model (Sigmodon hispidus).

Authors:  Joanna Pfeuffer; Karen Püschel; Volker ter Meulen; Jürgen Schneider-Schaulies; Stefan Niewiesk
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  Vesicular stomatitis virus glycoprotein containing the entire green fluorescent protein on its cytoplasmic domain is incorporated efficiently into virus particles.

Authors:  K P Dalton; J K Rose
Journal:  Virology       Date:  2001-01-20       Impact factor: 3.616

5.  Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months.

Authors:  H Gans; L Yasukawa; M Rinki; R DeHovitz; B Forghani; J Beeler; S Audet; Y Maldonado; A M Arvin
Journal:  J Infect Dis       Date:  2001-08-22       Impact factor: 5.226

6.  Successful mucosal immunization of cotton rats in the presence of measles virus-specific antibodies depends on degree of attenuation of vaccine vector and virus dose.

Authors:  Bernd Schlereth; Linda Buonocore; Annette Tietz; Volker Ter Meulen; John K Rose; Stefan Niewiesk
Journal:  J Gen Virol       Date:  2003-08       Impact factor: 3.891

7.  Newcastle disease virus V protein is a determinant of host range restriction.

Authors:  Man-Seong Park; Adolfo García-Sastre; Jerome F Cros; Christopher F Basler; Peter Palese
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

Review 8.  Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life.

Authors:  Hayley Gans; Ross DeHovitz; Bagher Forghani; Judith Beeler; Yvonne Maldonado; Ann M Arvin
Journal:  Vaccine       Date:  2003-07-28       Impact factor: 3.641

9.  Newcastle disease virus V protein is associated with viral pathogenesis and functions as an alpha interferon antagonist.

Authors:  Zhuhui Huang; Sateesh Krishnamurthy; Aruna Panda; Siba K Samal
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

10.  Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys.

Authors:  Sallie R Permar; Sherry A Klumpp; Keith G Mansfield; Woong-Ki Kim; Darci A Gorgone; Michelle A Lifton; Kenneth C Williams; Jörn E Schmitz; Keith A Reimann; Michael K Axthelm; Fernando P Polack; Diane E Griffin; Norman L Letvin
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

View more
  11 in total

1.  Type I interferon related genes are common genes on the early stage after vaccination by meta-analysis of microarray data.

Authors:  Junnan Zhang; Jie Shao; Xing Wu; Qunying Mao; Yiping Wang; Fan Gao; Wei Kong; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Decreased microRNA-140-5p contributes to respiratory syncytial virus disease through targeting Toll-like receptor 4.

Authors:  Yun Zhang; Lingyun Shao
Journal:  Exp Ther Med       Date:  2018-06-08       Impact factor: 2.447

Review 3.  Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

Authors:  Dmitriy Zamarin; Peter Palese
Journal:  Future Microbiol       Date:  2012-03       Impact factor: 3.165

4.  Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs.

Authors:  Sunil K Khattar; Sweety Samal; Anthony L Devico; Peter L Collins; Siba K Samal
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

5.  Synergistic induction of interferon α through TLR-3 and TLR-9 agonists stimulates immune responses against measles virus in neonatal cotton rats.

Authors:  Dhohyung Kim; Stefan Niewiesk
Journal:  Vaccine       Date:  2013-11-18       Impact factor: 3.641

6.  Success of measles virotherapy in ATL depends on type I interferon secretion and responsiveness.

Authors:  M Cecilia M Parrula; Soledad A Fernandez; Kristina Landes; Devra Huey; Michael Lairmore; Stefan Niewiesk
Journal:  Virus Res       Date:  2014-06-06       Impact factor: 3.303

7.  Rescue of recombinant Newcastle disease virus from cDNA.

Authors:  Juan Ayllon; Adolfo García-Sastre; Luis Martínez-Sobrido
Journal:  J Vis Exp       Date:  2013-10-11       Impact factor: 1.355

8.  Comparing the Primary and Recall Immune Response Induced by a New EV71 Vaccine Using Systems Biology Approaches.

Authors:  Jie Shao; Junnan Zhang; Xing Wu; Qunying Mao; Pan Chen; Fengcai Zhu; Miao Xu; Wei Kong; Zhenglun Liang; Junzhi Wang
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

9.  Synergistic induction of interferon α through TLR-3 and TLR-9 agonists identifies CD21 as interferon α receptor for the B cell response.

Authors:  Dhohyung Kim; Stefan Niewiesk
Journal:  PLoS Pathog       Date:  2013-03-14       Impact factor: 6.823

10.  Alpha/beta interferon receptor signaling amplifies early proinflammatory cytokine production in the lung during respiratory syncytial virus infection.

Authors:  Michelle Goritzka; Lydia R Durant; Catherine Pereira; Samira Salek-Ardakani; Peter J M Openshaw; Cecilia Johansson
Journal:  J Virol       Date:  2014-03-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.